Bimagrumab: What the Evidence Actually Shows

Bimagrumab isn't a peptide, and it isn't sold anywhere — it's a real, investigational, fully human monoclonal antibody that blocks activin type II receptors (ActRII), currently in active Phase 2 clinical development for obesity and muscle preservation. It has never been approved for any use, in any country. What makes it worth understanding here is a real, trial-documented profile that runs against the grain of every GLP-1 drug this site covers in depth: in its own human trials, it produces fat loss while INCREASING lean muscle mass, rather than the muscle loss that typically accompanies GLP-1-driven weight loss.

Not a peptide, and not for sale — an antibody, still in trials

Bimagrumab is a monoclonal antibody, not a peptide — it works by binding and blocking activin type II receptors (ActRIIA and ActRIIB), which normally respond to myostatin and activin A to LIMIT skeletal muscle growth. Blocking those receptors removes the brake, and muscle grows¹. It is administered by intravenous infusion, dosed by body weight (mg/kg), in a clinical trial setting only — it has no approved brand name, no approved indication, and no legal retail or compounded market anywhere. Nothing about it resembles the vial-and-diluent peptide products this site otherwise reviews.

The real ownership history — more complicated than one company

A live check of the ClinicalTrials.gov registry found a genuine, documented development history spanning two companies, not one. Bimagrumab (internal code BYM338) was originally developed by Novartis, which sponsored every bimagrumab trial through the mid-2010s for sporadic inclusion body myositis, sarcopenia, cachexia, and hip-fracture recovery². Novartis licensed bimagrumab's metabolic and obesity-focused development to Versanis Bio, a company Eli Lilly then acquired outright in 2023 — which is exactly why current obesity trials carry Lilly's own internal compound code (LY3985863) and list Versanis Bio, Inc. as a collaborator alongside Eli Lilly as lead sponsor, while Novartis continues separately-sponsored trials for other indications in parallel (a 2026 cardiac-safety study still lists Novartis as sponsor)²⁶. Both things are true at once: bimagrumab is a Novartis-originated molecule, and its current, most active obesity-focused development is Eli Lilly's.

A real efficacy failure worth stating plainly: inclusion body myositis

Before its metabolic pivot, bimagrumab's original target indication was sporadic inclusion body myositis (sIBM), a muscle-wasting disease with no effective therapy. Read directly from the pivotal trial's own long-term extension results, rather than a secondary summary: the RESILIENT trial's core study did not meet its primary endpoint (6-minute walk distance), and the extension study — up to 2 years of continued bimagrumab or placebo — was "terminated early due to core study not meeting its primary endpoint³." Its own stated conclusion: "did not provide clinical benefits in terms of improvement in mobility," despite a favorable long-term safety profile³. That's a real efficacy failure for that specific indication, reported here at the precision the primary source states it, because a secondary review this research checked characterized the same program in more flattering terms than the trial's own results support.

The muscle-preservation finding — what the actual trials show

This is the genuinely different profile the task asked to be verified rather than repeated from marketing language. Four real, independent data points, each sourced precisely:

Bimagrumab alone, in humans. The pivotal Phase 2 RCT (Novartis, 75 adults with type 2 diabetes and obesity, 48 weeks) found bimagrumab monotherapy produced fat mass loss of -20.5% (-7.5 kg) versus -0.5% (-0.18 kg) with placebo (P<.001) — and LEAN mass INCREASED 3.6% (+1.70 kg), versus a -0.8% decline with placebo (P<.001)⁴. Body weight fell 6.5% with bimagrumab versus 0.8% with placebo, and HbA1c improved significantly more too⁴. This wasn't muscle preservation during weight loss — it was fat loss with a lean-mass GAIN, in a real, controlled human trial.

Combined with a GLP-1 drug, in mice. A preclinical study (not human data — flagged as such here) found that adding bimagrumab to semaglutide in diet-induced obese mice produced superior fat loss than semaglutide alone, while preserving lean mass that semaglutide alone did not preserve⁵.

Combined with semaglutide, in humans — real trial results, not a press release. NCT05616013, a completed, Eli Lilly-sponsored Phase 2 RCT, tested bimagrumab and semaglutide alone and in combination in adults with overweight or obesity. Its results are posted directly on ClinicalTrials.gov as the sponsor's own mandatory federal disclosure — a primary source, though not a peer-reviewed journal article, a distinction this article states plainly rather than blurring the two. At week 48, semaglutide 2.4 mg alone produced a real weight-loss effect (-14.24% body weight) but a substantial lean-mass loss (-7.90% by DXA); adding 30 mg/kg bimagrumab to that same semaglutide dose produced GREATER weight loss (-17.79%) while cutting the lean-mass loss to -2.51% — roughly a two-thirds reduction in the muscle loss semaglutide alone caused, at a larger total weight-loss effect⁷. Bimagrumab alone (30 mg/kg, no semaglutide) again showed a lean-mass GAIN at week 48 (+2.39%) even while losing significant fat mass (-25.23% by DXA)⁷.

Cardiac safety, confirmed separately. A real concern with any muscle-growth-promoting therapy is cardiac muscle — the heart is muscle too. A 2026 Novartis-sponsored RCT in 68 healthy older adults (60-86 years) found no clinically relevant change in left ventricular mass index or ejection fraction after 6 months of bimagrumab versus placebo, while confirming the same body-composition pattern (lean mass +5.5%, fat mass -14%, both P<.001)⁶. Its own stated conclusion recommends "consideration of bimagrumab as a skeletal muscle sparing intervention in adults undergoing weight loss with GLP-1 receptor agonists⁶" — the exact use case this article is describing, stated by the trial's own authors, not implied by this article.

Current trial status — real, active Phase 2, not yet Phase 3

As of this review, no Phase 3 obesity trial for bimagrumab exists in the public ClinicalTrials.gov registry. The obesity-focused development program is real and active: one Phase 2 combination trial (with semaglutide) is complete with results posted; a second, larger Phase 2 trial (507 participants, combined and alone with tirzepatide) is active, not recruiting, with its primary completion date already passed as of this review and full results not yet posted; a separate Phase 2 combination trial was withdrawn; and an independent academic Phase 2 trial (Massachusetts General Hospital) is currently recruiting, with an estimated completion date of December 2028. Bimagrumab remains, at every level, an investigational compound — not approved, not sold, and not yet in late-stage development for obesity specifically.

Why this is genuinely different from the GLP-1 drugs this site covers

Every real GLP-1 or dual-agonist drug trial this site has reviewed — including tirzepatide vs. semaglutide's own head-to-head data — shows a meaningful share of total weight loss coming from lean mass, not just fat. Bimagrumab's own trial data, across three separate real sources, shows the opposite pattern for the antibody itself: fat loss with lean mass preserved or increased, both alone and in combination with a GLP-1 drug. That's a real, mechanistically distinct profile — worth understanding on its own terms as one of several next-generation approaches, alongside amycretin and VK2735, being tested for the next wave of obesity treatment, rather than mistaken for another GLP-1 drug or assumed to be available anywhere today.